Rhythm Biosciences (ASX:RHY) completed the initial integration of the Genetype business it acquired on Dec. 24, 2024, with the commercial processes required to provide and sell the geneType genetic risk assessment product restored, according to a Tuesday Australian bourse filing.
The integration was expected to take over 12 weeks earlier. Full integration is now expected to be completed by the end of February, per the filing.
The firm said the transition included the transfer, restoration, and rebuilding of several processes and supply partnerships.
The firm's shares fell past 2% in recent trading on Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。